查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863568

無血清培養基市場按產品類型、無血清培養基類型、細胞類型、配方、應用和最終用戶分類－2025-2030年全球預測

Serum-Free Media Market by Product Type, Serum-Free Media Type, Cell Type, Formulation, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2030 年，無血清培養基市場將成長至 44.7 億美元，複合年成長率為 10.07%。

關鍵市場統計數據
基準年 2024 25.1億美元
預計年份：2025年 27.6億美元
2030 年預測 44.7億美元
複合年成長率 (%) 10.07%

引人深思的引言將無血清培養基定位為一種平台技術，可實現可重複的細胞培養、可擴展的生物製程和更安全的生物製藥開發。

隨著科學技術進步、監管要求和商業性需求的共同作用，無血清培養基領域正在迅速發展，重塑細胞培養在研究和生產環境中的發展方式。無血清配方已從一種小眾技術解決方案轉變為基礎技術，能夠降低變異性、減輕生物風險並簡化下游製程。產業相關人員優先考慮明確的原料、可重複的性能以及與可擴展生物製程工作流程的兼容性，以支援更複雜的生物製藥、細胞和基因治療以及再生醫學應用。

培養基化學、分析特性分析和細胞生物學領域的技術進步正在拓展無血清培養基的功能範圍。這項進展得益於對細胞特異性營養需求的更深入理解、用於替代成分不明確的血清成分的新型賦形劑策略，以及原料品管的提升。因此，能夠將配方設計與細胞生物學和生產限制相結合的企業可以提高製程一致性並減少監管方面的阻力。在此背景下，目前對無血清培養基的評估不僅包括其生物學性能，還包括其供應鏈的穩健性（以滿足現代生產需求）以及與一次性系統、自動化和封閉式製程的兼容性。

科學進步、監管力度加大以及細胞療法的產業化，正將無血清培養基轉變為重要的生物製程促進因素。

在科學創新、細胞療法產業化以及監管機構對原料可追溯性的日益重視的推動下，無血清培養基領域正經歷著變革性的轉變。細胞株工程和系統生物學的進步推動了對針對特定細胞表現型定製配方的需求，使培養基的配方從「一刀切」式轉向能夠最佳化生產效率和關鍵品質屬性的客製化。同時，細胞和基因療法的產業化也催生了對能夠在大規模生產中保持穩定性能，同時又能滿足監管機構對一致且特性明確的原料的要求的培養基的需求。

此外，永續性和供應鏈韌性正日益成為優先事項。製造商正在減少動物性成分的使用，以應對倫理方面的擔憂並降低產品變異性。採購部門正在採用多源策略，以應對供應中斷。分析技術的創新，例如改進的代謝物分析和即時製程監控，能夠實現更精確的配方調整和更快的製程偏差排查。這些變化共同推動無血清培養基從特殊試劑迅速發展成為生物製程平台的關鍵組成部分，從而支持可重複性、法規遵循和營運擴充性。

評估關稅引發的供應鏈中斷對無血清培養基原料採購和物流的影響，以及對下游供應鏈和營運韌性的影響。

2025年公佈的一系列關稅政策的累積影響，為無血清成品的原料和成品供應鏈帶來了新的複雜性。影響試劑、胺基酸、特殊生長因子和包裝組件的關稅措施，可能會增加關鍵投入品的到岸成本並延長前置作業時間。為此，採購和供應鏈團隊正在優先考慮庫存策略、替代採購管道和供應商選擇活動，以確保供應的連續性，同時維持產品品質和合規性。

除了直接的成本壓力外，關稅也影響製造和表面處理工程的戰略定位決策。一些企業正在重新評估其區域採購基地，或考慮近岸外包，以降低關稅波動和運輸中斷帶來的風險。合規性仍然是重中之重，供應鏈重組必須保留可追溯性和變更控制的文件。因此，企業正在加大對供應商審核的投入，盡可能採用雙重採購，並加強合約保護以管理風險。總而言之，這些措施凸顯了一個更廣泛的趨勢，即建立更具韌性的供應鏈結構，以應對政策衝擊，同時滿足終端用戶對產品性能和安全的預期。

全面的細分分析揭示了細胞類型、產品結構、配方選擇、應用需求和最終用戶需求如何影響配方策略。

細分市場為解讀無血清培養基生態系中技術需求與商業性機會的交會點提供了一個系統性的觀點。在基於細胞類型的分類中，哺乳動物細胞和非哺乳動物細胞之間的區別對於配方設計至關重要，因為它們在營養利用、生長動力學和產品品質屬性方面存在顯著差異。哺乳動物細胞，包括CHO、HEK293、NS0和Vero細胞，對滲透壓、生長因子和添加劑的需求各不相同，這些需求會影響細胞生產力和轉譯後修飾。非哺乳動物細胞，以昆蟲細胞和酵母細胞為代表，具有不同的代謝需求和耐受性，通常能夠降低成本，但也需要不同的緩衝和碳源策略。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 化學成分明確、無血清培養基的出現，為實現穩定的生物製藥生產提供了可能。
  • 革命性的無血清培養基配方可提高生物製藥生產整體不同細胞株的特異性性能
  • 幹細胞和再生醫學研究中對無血清培養基的需求日益成長
  • 將最佳化的無血清培養基與一次性生物反應器結合，以實現細胞治療的規模化生產。
  • 快速投資本地生產能力，以減少對進口無血清培養基的依賴
  • 在全球建立無血清培養基分銷網路，以支持各地區生物製品生產的擴張。
  • 提高科學家和工程師對含血清培養基相關污染風險的認知
  • 透過培養基開發公司與研究機構之間的夥伴關係，共同開發客製化的無血清培養基。
  • 生產技術的進步提高了產量並降低了總製造成本。
  • 政府積極主導並提供資金，支持先進治療方法和疫苗的研發。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依產品類型分類的無血清培養基市場

  • 客製化媒體
  • 定義媒體

9. 依無血清培養基類型分類的無血清培養基市場

  • 化學成分明確的培養基（CDM）
  • 常用無血清培養基（SFM）
  • 非動物源性（NAO）培養基
  • 無蛋白培養基（PFM）
  • 無異種成分培養基

第10章：以細胞類型分類的無血清培養基市場

  • 哺乳動物細胞
    • CHO細胞
      • CHO-DG44
      • CHO-DXB11
      • CHO-K1
    • HEK293
    • NS0細胞
    • Vero細胞
  • 非哺乳動物細胞
    • 昆蟲細胞
    • 酵母菌細胞

第11章 依配方分類的無血清培養基市場

  • 液態
  • 粉狀

第12章 無血清培養基市場依應用領域分類

  • 學術研究
    • 基因編輯
    • 幹細胞研究
  • 生物製藥生產
    • 單株抗體
    • 重組蛋白
    • 疫苗
  • 細胞和基因治療
    • CAR-T療法
    • 幹細胞療法
  • 組織工程與再生醫學

第13章 依最終用戶分類的無血清培養基市場

  • 生技公司
  • 受託研究機構
  • 製藥公司

第14章 各地區的無血清培養基市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 無血清培養基市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國無血清培養基市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Ajinomoto Co., Inc.
    • Becton, Dickinson and Company
    • Bio-Techne Corporation
    • Corning Incorporated
    • Danahar Corporation
    • FUJIFILM Holdings Corporation
    • Lonza Group AG
    • Merck KGaA
    • Sartorius AG
    • STEMCELL Technologies Canada Inc.
    • Thermo Fisher Scientific Inc.
    • MP Biomedicals, LLC
Product Code: MRR-7C31448F0BA9

The Serum-Free Media Market is projected to grow by USD 4.47 billion at a CAGR of 10.07% by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.51 billion
Estimated Year [2025] USD 2.76 billion
Forecast Year [2030] USD 4.47 billion
CAGR (%) 10.07%

An insightful introduction that frames serum-free media as a cornerstone enabling reproducible cell culture, scalable bioprocessing, and safer biologics development

The serum-free media landscape is evolving rapidly as scientific advances, regulatory expectations, and commercial imperatives converge to reshape how cell culture is performed across research and production environments. Serum-free formulations have transitioned from niche technical solutions to foundational enabling technologies that reduce variability, mitigate biological risks, and streamline downstream processing. Industry stakeholders are prioritizing defined inputs, reproducible performance, and compatibility with scalable bioprocessing workflows in order to support higher-complexity biologics, cell and gene therapies, and regenerative medicine applications.

Technological progress in media chemistry, analytical characterization, and cell biology has expanded the functional footprint of serum-free solutions. This progress is underpinned by increased understanding of cell-specific nutrient requirements, novel supplement strategies that replace poorly defined serum components, and a stronger emphasis on quality control across raw materials. Consequently, organizations that align formulation design with cell biology and manufacturing constraints can improve process consistency and reduce regulatory friction. As a result, serum-free media are now evaluated not only for biological performance but also for supply-chain robustness and compatibility with single-use systems, automation, and closed processing to meet contemporary production needs.

How scientific advancements, regulatory scrutiny, and industrialization of cell therapies are reshaping serum-free media into a strategic bioprocess enabler

The landscape for serum-free media is undergoing transformative shifts driven by scientific innovation, industrialization of cell therapies, and heightened regulatory attention to raw material traceability. Advances in cell-line engineering and systems biology have increased demand for formulations tailored to specific cellular phenotypes, moving away from one-size-fits-all recipes toward bespoke media that optimize productivity and critical quality attributes. Concurrently, the industrialization of cell and gene therapies has created pressure for media that perform robustly at scale while supporting regulatory dossiers that require consistent, well-characterized inputs.

In addition, sustainability and supply-chain resilience are rising priorities. Manufacturers are targeting reduction of animal-derived components to address ethical concerns and reduce variability, while procurement teams are adopting multi-sourcing strategies to guard against disruptions. Analytical innovations, including improved metabolite profiling and real-time process monitoring, enable more precise formulation tuning and faster troubleshooting of process drift. Taken together, these shifts are accelerating the maturation of serum-free media from a specialized reagent into a strategic component of bioprocess platforms that supports reproducibility, regulatory compliance, and operational scalability.

Evaluating the downstream supply chain and operational resilience consequences stemming from tariff-driven disruptions affecting serum-free media inputs and logistics

The cumulative impact of tariff policies announced for 2025 has introduced new complexity into supply chains for raw materials and finished serum-free formulations. Tariff measures affecting reagents, amino acids, specialized growth factors, and packaging components have the potential to increase landed costs and extend lead times for critical inputs. In response, procurement and supply chain teams are prioritizing inventory strategies, alternative sourcing, and supplier qualification activities to maintain continuity of supply while preserving product quality and compliance.

Beyond immediate cost pressures, tariffs influence strategic location decisions for manufacturing and fill-finish operations. Some organizations are reassessing regional sourcing hubs and considering nearshoring to reduce exposure to tariff volatility and transport disruptions. Regulatory compliance considerations remain paramount, as any supply-chain realignment must preserve documentation for traceability and change control. As a consequence, companies are investing in enhanced supplier audits, dual-sourcing where feasible, and tighter contractual protections to manage risk. Collectively, these responses underscore a broader trend toward resilient supply architectures designed to absorb policy-driven shocks while maintaining the performance and safety that end-users expect.

Comprehensive segmentation insights revealing how cell type, product architecture, formulation choices, application demands, and end-user needs shape formulation strategies

Segmentation provides a structured lens to interpret where technical demand and commercial opportunity intersect within the serum-free media ecosystem. Based on cell type, distinctions between Mammalian Cells and Non-Mammalian Cells are central to formulation design because nutrient utilization, growth kinetics, and product quality attributes differ markedly. Mammalian Cells, including CHO Cells, HEK293, NS0 Cells, and Vero Cells, present diverse requirements for osmolality, growth factors, and supplements that influence productivity and post-translational modifications. Non-Mammalian Cells, exemplified by Insect Cells and Yeast Cells, impose different metabolic demands and tolerance profiles, often enabling cost efficiencies but requiring alternative buffering and carbon source strategies.

Based on product type, differentiation between Custom Media and Defined Media drives procurement and R&D priorities. Custom Media solutions are tailored for specific cell lines or product goals and often require deeper analytical support and iterative optimization, whereas Defined Media prioritize reproducibility and regulatory clarity by minimizing undefined components. Based on formulation, choices between Liquid Form and Powdered Form have operational implications: liquid formats deliver convenience and reduced reconstitution variability but involve higher transport volumes and cold-chain considerations, while powdered formats offer storage and logistics advantages alongside on-site reconstitution needs.

Based on application, academic research, biopharmaceutical production, cell & gene therapy, and tissue engineering each demand unique performance attributes. Academic Research applications, including Gene Editing and Stem Cell Research, value flexibility and experimental reproducibility. Biopharmaceutical Production subsegments-Monoclonal Antibodies, Recombinant Proteins, and Vaccines-prioritize process consistency, scalability, and regulatory documentation. Cell & Gene Therapy areas such as CAR-T Therapy and Stem Cell Therapy require media that support cell viability, functionality, and safety in clinical manufacturing. Finally, based on end user, requirements differ across Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, with each class placing distinct emphasis on speed-to-data, regulatory readiness, and scalable supply.

Regional dynamics and regulatory landscapes that determine adoption patterns, supply-chain strategies, and development priorities across global regions

Regional dynamics significantly influence how serum-free media are developed, produced, and adopted across different ecosystems. The Americas exhibit strong integration between academic innovation hubs, contract development and manufacturing organizations, and large-scale biopharmaceutical production facilities, which together drive demand for formulations that are compatible with GMP environments and scalable manufacturing workflows. Regulatory systems and established supply-chain networks in this region also support rapid translation from lab to clinic.

Europe, Middle East & Africa blends stringent regulatory oversight with a diverse supplier base and growing investment in advanced therapies. In this region, emphasis on traceability, ethical sourcing, and compliance with complex regulatory frameworks encourages adoption of highly characterized, defined formulations. The need for harmonized documentation and environmental sustainability considerations also shapes procurement decisions.

Asia-Pacific combines accelerating biopharmaceutical development with manufacturing capacity expansion and rapidly evolving regulatory frameworks. Local demand for cost-effective and high-performance media is rising in parallel with investments in indigenous cell therapy programs and vaccine production. Moreover, partnerships between multinational firms and regional manufacturers are influencing formulation availability and local qualification processes. Across all regions, strategic considerations such as supply-chain localization, regulatory harmonization, and talent development remain central to successful deployment of serum-free solutions.

Competitive and corporate strategies shaping product innovation, partnerships, and quality-driven differentiation in the serum-free media ecosystem

Competitive dynamics in the serum-free media space are shaped by companies that combine formulation expertise, regulatory know-how, and supply-chain capabilities. Leading organizations are investing in application-specific media, launching products that target high-value therapeutic segments, and expanding analytical services to support customer qualification. Strategic partnerships with contract development and manufacturing organizations and academic centers of excellence are common, enabling faster validation and route-to-market for specialized formulations.

Innovation pathways include modular product architectures that enable rapid customization, licensing models that facilitate co-development, and service offerings that bundle technical support, method transfer, and stability data. In parallel, manufacturers are placing emphasis on raw material traceability and supplier transparency to meet the heightened expectations of regulatory agencies and forward-looking customers. Companies that integrate robust quality management systems with agile commercial and technical support functions are positioned to win in environments where performance, documentation, and continuity of supply converge as decisive buyer criteria.

Practical recommendations for R&D, supply chain, regulatory, and commercial leaders to build resilience, accelerate adoption, and improve product-market fit

To capture strategic value, industry leaders should adopt a set of coordinated actions that align R&D, supply chain, and commercial functions. First, prioritize investments in analytical platforms and cell-specific formulation science to accelerate development cycles and reduce risk during scale-up. Equally important is the development of flexible manufacturing strategies that include dual sourcing for critical inputs and options for regional production to mitigate policy and logistics disruptions.

Next, reinforce regulatory and quality frameworks by documenting raw material provenance, implementing comprehensive supplier qualification programs, and maintaining robust change control processes to expedite regulatory submissions. From a commercial perspective, offer tiered product and service packages that address the distinct needs of academic labs, CDMOs, and pharmaceutical manufacturers, thereby improving customer retention and enabling premium service offerings. Finally, foster collaborative ecosystems with academic centers and clinical partners to validate formulations in relevant applications, create shared data assets, and accelerate adoption across translational pathways. Together, these measures increase resilience, improve product-market fit, and support sustainable growth.

A rigorous, multi-source research methodology combining expert interviews, technical literature, and stakeholder validation to ensure reliable and actionable insights

The research approach integrates qualitative expert interviews, technical literature synthesis, and primary engagement with stakeholders across R&D, manufacturing, and procurement to produce a nuanced perspective on the serum-free media landscape. Data collection included structured conversations with formulation scientists, process development leaders, and procurement specialists, complemented by review of peer-reviewed publications, regulatory guidance, and company disclosures that clarify product attributes and validation pathways.

Analytical methods emphasized triangulation to ensure findings reflect operational realities: cross-validation of technical performance claims with independent laboratory reports, comparison of supplier capabilities against documented quality systems, and mapping of application requirements to formulation characteristics. For segmentation and regional analysis, the methodology relied on direct input from end users and service providers to identify demand drivers and operational constraints. Throughout, the research adhered to rigorous standards for source attribution, methodological transparency, and reproducibility so readers can evaluate the alignment of insights with their own data and priorities.

Concluding synthesis that emphasizes serum-free media as a strategic, resilient, and application-driven component of modern cell culture and biologics development

In summary, serum-free media are transitioning from technical enablers to strategic assets that influence development speed, product quality, and manufacturing resilience. Scientific advances in cell biology and analytics are enabling more tailored formulations that meet the diverse needs of mammalian and non-mammalian systems, while formulation formats and product types are being selected to balance operational convenience with regulatory clarity. Regional differences in regulatory expectations and manufacturing capacity shape adoption trajectories, and evolving trade policies are prompting companies to shore up supply chains and consider localization where appropriate.

Moving forward, organizations that invest in application-specific R&D, strengthen supplier transparency, and align commercial models to end-user needs will be best positioned to deliver value. Integration of high-quality analytical data with collaborative partnerships will accelerate qualification and adoption, and careful attention to operational resilience will mitigate the impact of policy and logistics disruptions. Collectively, these elements point to a future where serum-free media are integral to reproducible science and scalable biologics manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of chemically defined serum-free media for consistent biopharmaceutical production
  • 5.2. Innovation in serum free formulations enabling enhanced cell line specific performance across biopharmaceutical manufacturing
  • 5.3. Rising demand for serum free media in stem cell and regenerative medicine research
  • 5.4. Integration of single-use bioreactors with optimized serum-free media for cell therapy scale-up
  • 5.5. Surging investments in localized manufacturing capabilities to reduce dependency on imported serum free media
  • 5.6. Global expansion of serum free media distribution networks to support regional bioproduction growth
  • 5.7. Increasing awareness among scientists and technicians regarding contamination risks associated with serum based media
  • 5.8. Collaborative partnerships between media developers and research institutions to co develop customized serum free solutions
  • 5.9. Evolving production technologies aimed at enhancing yield and reducing overall cost of goods
  • 5.10. Proactive government initiatives and funding supporting advanced therapy and vaccine development

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Serum-Free Media Market, by Product Type

  • 8.1. Custom Media
  • 8.2. Defined Media

9. Serum-Free Media Market, by Serum-Free Media Type

  • 9.1. Chemically Defined Media (CDM)
  • 9.2. Common Serum-Free Media (SFM)
  • 9.3. Non-Animal Origin (NAO) Media
  • 9.4. Protein-Free Media (PFM)
  • 9.5. Xeno-Free Media

10. Serum-Free Media Market, by Cell Type

  • 10.1. Mammalian Cells
    • 10.1.1. CHO Cells
      • 10.1.1.1. CHO-DG44
      • 10.1.1.2. CHO-DXB11
      • 10.1.1.3. CHO-K1
    • 10.1.2. HEK293
    • 10.1.3. NS0 Cells
    • 10.1.4. Vero Cells
  • 10.2. Non-Mammalian Cells
    • 10.2.1. Insect Cells
    • 10.2.2. Yeast Cells

11. Serum-Free Media Market, by Formulation

  • 11.1. Liquid Form
  • 11.2. Powdered Form

12. Serum-Free Media Market, by Application

  • 12.1. Academic Research
    • 12.1.1. Gene Editing
    • 12.1.2. Stem Cell Research
  • 12.2. Biopharmaceutical Production
    • 12.2.1. Monoclonal Antibodies
    • 12.2.2. Recombinant Proteins
    • 12.2.3. Vaccines
  • 12.3. Cell & Gene Therapy
    • 12.3.1. CAR-T Therapy
    • 12.3.2. Stem Cell Therapy
  • 12.4. Tissue Engineering & Regenerative Medicine

13. Serum-Free Media Market, by End User

  • 13.1. Biotechnology Companies
  • 13.2. Contract Research Organizations
  • 13.3. Pharmaceutical Companies

14. Serum-Free Media Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Serum-Free Media Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Serum-Free Media Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Ajinomoto Co., Inc.
    • 17.3.2. Becton, Dickinson and Company
    • 17.3.3. Bio-Techne Corporation
    • 17.3.4. Corning Incorporated
    • 17.3.5. Danahar Corporation
    • 17.3.6. FUJIFILM Holdings Corporation
    • 17.3.7. Lonza Group AG
    • 17.3.8. Merck KGaA
    • 17.3.9. Sartorius AG
    • 17.3.10. STEMCELL Technologies Canada Inc.
    • 17.3.11. Thermo Fisher Scientific Inc.
    • 17.3.12. MP Biomedicals, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 3. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2024 VS 2030 (%)
  • FIGURE 5. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2024 VS 2030 (%)
  • FIGURE 7. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. GCC SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. BRICS SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. G7 SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. NATO SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. SERUM-FREE MEDIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. SERUM-FREE MEDIA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SERUM-FREE MEDIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SERUM-FREE MEDIA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SERUM-FREE MEDIA MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 181. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 183. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 185. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 187. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 189. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 191. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 193. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 195. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 197. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 199. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 201. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 203. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 205. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 207. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 209. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 211. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 213. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 215. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 217. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 219. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 221. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 223. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 225. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 227. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 229. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2030 (USD MILLION)
  • TABLE 231. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 233. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 235. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2025-2030 (USD MILLION)
  • TABLE 237. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 245. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2025-2030 (USD MILLION)
  • TABLE 247. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 249. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 251. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 253. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 255. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2025-2030 (USD MILLION)
  • TABLE 257. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 259. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 261. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 263. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 271. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2025-2030 (USD MILLION)
  • TABLE 273. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 275. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 277. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 279. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 281. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2025-2030 (USD MILLION)
  • TABLE 283. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 285. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 287. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 289. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2025-2030 (USD MILLION)
  • TABLE 293. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 297. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2025-2030 (USD MILLION)
  • TABLE 299. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 301. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 303. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 305. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2025-2030 (USD MILLION)
  • TABLE 307. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2025-2030 (USD MILLION)
  • TABLE 309. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 311. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2025-2030 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2025-2030 (USD MILLION)
  • TABLE 323. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE,